2023
A randomized clinical trial assessing the effect of automated medication-targeted alerts on acute kidney injury outcomes
Wilson F, Yamamoto Y, Martin M, Coronel-Moreno C, Li F, Cheng C, Aklilu A, Ghazi L, Greenberg J, Latham S, Melchinger H, Mansour S, Moledina D, Parikh C, Partridge C, Testani J, Ugwuowo U. A randomized clinical trial assessing the effect of automated medication-targeted alerts on acute kidney injury outcomes. Nature Communications 2023, 14: 2826. PMID: 37198160, PMCID: PMC10192367, DOI: 10.1038/s41467-023-38532-3.Peer-Reviewed Original ResearchConceptsAcute kidney injuryUsual care groupKidney injuryCare groupAcute Kidney Injury OutcomesAlert groupNon-steroidal anti-inflammatory drugsComposite of progressionHours of randomizationMedications of interestAldosterone system inhibitorsClasses of medicationsProton pump inhibitorsRandomized clinical trialsAnti-inflammatory drugsClinical decision support systemNephrotoxic medicationsHospitalized adultsDiscontinuation ratesCertain medicationsPrimary outcomeSubstantial morbiditySystem inhibitorsPump inhibitorsParallel group
2016
PPIs and kidney disease: from AIN to CKD
Moledina DG, Perazella MA. PPIs and kidney disease: from AIN to CKD. Journal Of Nephrology 2016, 29: 611-616. PMID: 27072818, DOI: 10.1007/s40620-016-0309-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute interstitial nephritisProton pump inhibitorsChronic kidney diseaseKidney diseaseDrug-induced acute interstitial nephritisExcellent overall safety profileHigher CKD riskSystemic allergic manifestationsAcute kidney injuryAdverse renal eventsGlomerular filtration rateOverall safety profilePopulation-based studyMillions of patientsAIN diagnosisRenal eventsCKD riskKidney injuryAllergic manifestationsInterstitial nephritisMedian timeSafety profileDrug initiationKidney failurePump inhibitors